1. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach
- Author
-
John Z. Duan, Ping Zhao, and Andre J. Jackson
- Subjects
Metabolic Clearance Rate ,Midazolam ,Population ,Biological Availability ,Pharmacology ,Models, Biological ,Pharmacokinetics ,medicine ,Cytochrome P-450 CYP3A ,Humans ,Pharmacology (medical) ,Computer Simulation ,Drug Interactions ,education ,Biotransformation ,Volume of distribution ,education.field_of_study ,Chemistry ,Drug interaction ,NONMEM ,Bioavailability ,Ketoconazole ,Cytochrome P-450 CYP3A Inhibitors ,Algorithms ,medicine.drug - Abstract
Applying a comedication (COMD) covariate to apparent clearance (CL(app) = CL/F) is a common practice when using population pharmacokinetics (PopPK) to study metabolism-based drug-drug interactions (DDI). This study evaluates the importance of independently applying COMD to F and CL to account for DDI at the level of first-pass metabolism. A known DDI between single oral doses of the CYP3A substrate midazolam (5 mg) and the inhibitor ketoconazole (400 mg) was simulated using a physiologically based pharmacokinetic simulator SimCyp in virtual subjects. The simulated midazolam data were analyzed by PopPK method under the following scenarios by applying COMD effect to (1) CL(app) only, (2) CL and F, and (3) CL(app) and apparent volume of distribution (V(app) = V/F), assuming V is unchanged. The mean simulated degree of interaction, measured by midazolam AUC ratio with and without ketoconazole (AUCR), was 10.28. Scenario 1 underestimated AUCR. When COMD was independently applied to F and V(app) in scenarios 2 and 3, lower objective function values of the PopPK analysis and more accurate AUCR estimates were achieved. AUCR estimates were also dependent on sampling. The authors conclude that when significant inhibition of the first-pass metabolism of the substrate is anticipated, COMD effects should be applied to both CL and F in PopPK analysis.
- Published
- 2010